These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 3709959)

  • 1. Pre-clinical microbiology and pharmacology of norfloxacin.
    Gadebusch HH
    Biochem Soc Trans; 1986 Apr; 14(2):501-3. PubMed ID: 3709959
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro activity of ciprofloxacin, norfloxacin, and ofloxacin against multi-resistant Enterobacteriaceae.
    Niculescu E; Wagener H
    Chemioterapia; 1987 Jun; 6(2 Suppl):132-3. PubMed ID: 3509369
    [No Abstract]   [Full Text] [Related]  

  • 3. [In vitro evaluation of norfloxacin on clinically isolated bacterial strains].
    Chiaradia V; Romeo AA; Pascoli L; Santini G
    Nuovi Ann Ig Microbiol; 1984; 35(6):471-81. PubMed ID: 6545701
    [No Abstract]   [Full Text] [Related]  

  • 4. [Activity of norfloxacin against gram-negative bacteria].
    Ben Redjeb S; Ennaifer M; Kechrid A; Ben Hassen A; Boujnah A
    Tunis Med; 1989; 67(6-7):391-5. PubMed ID: 2508283
    [No Abstract]   [Full Text] [Related]  

  • 5. Antibacterial activity of norfloxacin against 1700 relatively resistant clinical isolates.
    Qadri SM; Lee G; Brodie L
    Drugs Exp Clin Res; 1989; 15(8):349-53. PubMed ID: 2598776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility of urinary pathogens to quinolones compared to other antimicrobial agents.
    Osman LM; Sabbour MS; el-Baz F
    Chemioterapia; 1987 Jun; 6(2 Suppl):147-8. PubMed ID: 3151335
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro activity of aryl fluoroquinolones, Abbott 56619 and Abbott 56620, compared to ciprofloxacin, norfloxacin and beta-lactams versus multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Meyer RD; Liu S
    Chemotherapy; 1986; 32(5):425-30. PubMed ID: 3093154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibacterial activity and pharmacokinetics in mice of two new derivatives of norfloxacin.
    Balsari A; Dubini F; Stradi R; Riviera L
    Chemioterapia; 1987 Jun; 6(2 Suppl):176-8. PubMed ID: 3509384
    [No Abstract]   [Full Text] [Related]  

  • 9. Antimicrobial activity of norfloxacin in enteric and urinary tract infections: combined effect of norfloxacin with aminoglycosides, tetracycline and chloramphenicol.
    Mascellino MT; Lorenzi A; Bonanni M; Iegri F
    Drugs Exp Clin Res; 1986; 12(4):319-23. PubMed ID: 3720519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1-Chloropiperazinic derivative (ER 311) of norfloxacin: antibacterial activity in vitro and pharmacokinetic properties in mice.
    Dubini F; Balsari A; Stradi R; Riviera L
    Chemioterapia; 1987 Jun; 6(2 Suppl):178-80. PubMed ID: 3509385
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibacterial activity after a single-dose of norfloxacin, ofloxacin and pipemidic acid detected in urine of volunteers.
    Cruciani M; Monzillo V; Navarra A; Tinelli C; Concia E
    Drugs Exp Clin Res; 1988; 14(8):533-7. PubMed ID: 3150350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of fleroxacin compared with three other quinolones.
    Bremner DA; Dickie AS; Singh KP
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():19-23. PubMed ID: 3144536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparative in vitro activity of ofloxacin (RU 43 280) and other quinolone derivatives against 722 bacteria of clinical interest.
    Santos Ferreira M; Vital J
    Chemioterapia; 1987 Jun; 6(2 Suppl):145-7. PubMed ID: 2908239
    [No Abstract]   [Full Text] [Related]  

  • 14. In-vitro activity of pefloxacin compared with six other quinolones.
    Ligtvoet EE; Wickerhoff-Minoggio T
    J Antimicrob Chemother; 1985 Oct; 16(4):485-90. PubMed ID: 3864776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid.
    Vuye A
    Arzneimittelforschung; 1983; 33(12):1623-7. PubMed ID: 6230083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in-vitro activity of rufloxacin with five other antimicrobial agents against bacterial enteric pathogens.
    Soriano F; Fernández-Roblas R; López JC; García-Corbeira P; Aguilar L
    J Antimicrob Chemother; 1994 Jul; 34(1):157-60. PubMed ID: 7961202
    [No Abstract]   [Full Text] [Related]  

  • 17. [Quinolones: antimicrobials for the 90s].
    Timerman A
    AMB Rev Assoc Med Bras; 1987; 33(5-6):81-2. PubMed ID: 3502367
    [No Abstract]   [Full Text] [Related]  

  • 18. Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic model simulating urine concentrations obtained after 2000/125 mg sustained-release co-amoxiclav and 400 mg norfloxacin administration.
    Alou L; Aguilar L; Sevillano D; Giménez MJ; Cafini F; Valero E; Relaño MT; Prieto J
    J Antimicrob Chemother; 2006 Apr; 57(4):714-9. PubMed ID: 16492718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
    Croize J; Le Noc P; Bryskier A; Robert J
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibacterial activity of norfloxacin against bacterial isolates from the urinary tract.
    Qadri SM; Johnson S
    J Natl Med Assoc; 1989 Apr; 81(4):382-5. PubMed ID: 2738947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.